Lunit Surpasses 1 Million Mammograms in U.S. One Year After Volpara Acquisition

Building on Volpara's breast health expertise, Lunit strengthens its U.S. presence—now delivering AI-powered breast cancer screening across 200 imaging sites

SEOUL, South Korea, May 19, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and therapeutics, today announced major milestones in the United States, one year after its acquisition of Volpara Health Technologies.

Since acquiring Volpara, Lunit has significantly expanded its presence across North America. By June 2025, Lunit's AI solutions for digital breast tomosynthesis (Lunit INSIGHT DBT) and mammography analysis (Lunit INSIGHT MMG) will be deployed at over 200 imaging centers and hospitals across the U.S., with approximately 350 to 400 radiologists utilizing its technology.

Together, Lunit and Volpara now power more than one million annual mammograms across North America — a major step forward in the company's U.S. growth strategy.

Lunit's growing customer base includes leading healthcare providers such as Rezolut, SimonMed Imaging, and UC Davis Health, reflecting its strengthening position in the U.S. medical imaging market.

In addition to its expanding U.S. footprint, Lunit and Volpara introduced the concept of a comprehensive Ecosystem for Cancer Detection and Care at RSNA 2024. The Ecosystem is designed to unify AI technologies for lesion detection, workflow optimization, quality control, and patient engagement—empowering clinicians with actionable insights and scalable solutions across the cancer care continuum.

Lunit and Volpara also demonstrated the complementary value of combining Lunit INSIGHT Risk and Volpara Risk Pathways at RSNA 2024—offering a glimpse into how imaging-based and clinical data may be used together to personalize breast cancer risk assessment. The two solutions were shown as a prototype to work in tandem, that would predict the likelihood of breast cancer development within 1 to 5 years, to enable earlier interventions, more personalized care, and redefine standards for breast cancer screening and management.

"The successful integration of Lunit and Volpara has accelerated our mission to transform cancer diagnostics globally, and the momentum we've built in the United States marks just the beginning," said Brandon Suh, CEO of Lunit. "By combining Lunit's AI innovation with Volpara's breast health expertise, we're delivering a new standard of comprehensive support for clinicians—enhancing early detection, improving screening quality, optimizing workflows, and ultimately helping providers deliver better outcomes for patients worldwide. With our expanded footprint and comprehensive ecosystem, we are poised to lead the future of cancer care."

Lunit plans to further expand its U.S. operations, building on its strong foundation with next-generation AI solutions, dedicated clinical support, and a growing ecosystem designed to shape the future of cancer detection and care.

About Lunit

Founded in 2013, Lunit (KRX:328130.KQ) is a global leader in AI for cancer diagnostics and therapeutics. With a mission to conquer cancer through AI, Lunit develops AI-powered solutions for medical imaging and biomarker analysis to enable precise diagnosis and personalized treatment. Lunit's FDA-cleared Lunit INSIGHT suite supports cancer screening at over 4,800 medical institutions in more than 55 countries. Lunit clinical studies have been featured in top-tier journals—including The Lancet Digital Health and Journal of Clinical Oncology—and presented at major conferences such as ASCO and RSNA. Headquartered in Seoul with global offices, Lunit is driving the worldwide fight against cancer. Learn more at lunit.io.

SOURCE Lunit